hATTR Amyloidosis CNS Drug Pipeline — PatSnap Eureka
Brain-Penetrant TTR Silencing & Next-Generation hATTR Therapies
Approved liver-targeting therapies cannot reach TTR produced by the choroid plexus — leaving CNS and oculoleptomeningeal amyloidosis entirely undertreated. Explore the full pipeline of stabilizers, RNAi agents, ASOs, and emerging CNS-directed approaches.
The CNS Sanctuary Problem in hATTR Amyloidosis
Hereditary transthyretin amyloidosis (hATTR) is a rare, autosomal dominant, fatal protein-misfolding disorder caused by mutations in the TTR gene, resulting in systemic amyloid deposition that drives progressive polyneuropathy and cardiomyopathy. The rate-limiting pathogenic step is tetramer dissociation into partially unfolded monomers that self-assemble into amyloid fibrils, driven by destabilizing missense mutations. Over 130 TTR point mutations have been documented, of which Val30Met (V30M) is the most prevalent globally.
TTR is synthesized predominantly by the liver (approximately 90% of circulating protein), with additional production in the choroid plexus — secreted into cerebrospinal fluid (CSF) — and the retinal pigment epithelium. According to a 2021 paper from Heidelberg University Hospital: "certain TTR variants… favor disease manifestations in the central nervous system (CNS) or eyes, which is mostly associated with TTR production in the choroid plexus and retina. These compartments cannot be sufficiently reached by any of the approved medications."
CNS amyloidosis is a distinct disease manifestation — encompassing leptomeningeal amyloidosis, focal neurological episodes, dementia, cerebrovascular bleeding, and seizures — arising approximately a decade after peripheral disease onset in many variant carriers. Liver transplantation, which eliminates hepatic mutant TTR production, leaves choroid plexus TTR intact, and clinical observations document continued CNS amyloid deposition post-transplant, confirming choroid plexus TTR as a clinically validated independent target. Learn more about life sciences innovation intelligence at PatSnap.
The European Medicines Agency and regulatory agencies globally have approved therapies targeting hepatic TTR — but the CNS sanctuary remains pharmacologically inaccessible, making it the defining unmet need driving next-generation pipeline activity.
hATTR Pipeline: From Approved Agents to CNS-Directed Approaches
Six distinct therapeutic modalities are active in the hATTR amyloidosis pipeline, ranging from approved small-molecule stabilizers to preclinical brain-penetrant and choroid plexus-directed silencing strategies.
TTR Tetramer Kinetic Stabilizers
Small molecules occupy the two thyroxine (T4)-binding pockets at the dimer interface of the TTR tetramer, preventing rate-limiting dissociation. Tafamidis (benzoxazole derivative) is the reference compound — approved for FAP and ATTR-CM. A 2023 Scripps study found tafamidis CSF concentrations at approved doses (20 mg or 80 mg QD) are insufficient to stabilize TTR in the CSF compartment, driving next-generation CNS-penetrant stabilizer development.
Tafamidis: ApprovedTolcapone / SOM0226 — Brain-Penetrant Stabilizer
Tolcapone, an FDA-approved COMT inhibitor for Parkinson's disease, demonstrates superior binding to the TTR T4 pocket versus tafamidis in crystal structures. Its BBB permeability distinguishes it mechanistically from tafamidis. A Corino Therapeutics US patent (2021) explicitly claims methods of stabilizing TTR tetramers in CSF via BBB-crossing COMT inhibitors. SOM Innovation Biotech holds 10+ patents across US, EP, AU, SG jurisdictions (2012–2023) covering COMT inhibitors for TTR amyloidosis.
Clinical Trials ReferencedRNA Interference — Hepatic TTR Silencing
Alnylam's patisiran (LNP-encapsulated siRNA) and GalNAc-siRNA conjugates degrade hepatic TTR mRNA via RISC, reducing serum TTR by >80–91% in clinical trials. A Phase 3b open-label trial documented 91% median serum TTR reduction in post-liver-transplant ATTRv-PN patients. An Alnylam WO patent (2025) explicitly extends dsRNA indications to leptomeningeal/CNS amyloidosis, signaling active IP expansion into non-hepatic CNS indication space.
Patisiran: ApprovedAntisense Oligonucleotides — Hepatic & Choroid Plexus
Inotersen (approved) and eplontersen (AKCEA-TTR-LRx, Phase 3 NEURO-TTRansform) reduce hepatic TTR mRNA. GalNAc conjugation on eplontersen improves potency for lower, less frequent dosing. Critically, a 2012 ISIS Pharmaceuticals HK patent explicitly claims oligonucleotides targeting TTR expression in the choroid plexus, not just the liver — representing an early IP signal for CSF-route CNS TTR silencing. "Reduction of TTR in the choroid plexus could result in the reduction of amyloid deposits and fibril formation" in the brain.
Eplontersen: Phase 3Retinal Pigment Epithelium siRNA Delivery
Kumamoto University holds patents (EP, CA, AU, WO; 2011–2015) covering siRNA delivery targeting TTR expression in the retinal pigment epithelium (RPE) for ocular amyloidosis. Double-stranded RNA administered directly to the RPE establishes a tissue-specific silencing precedent relevant to eye and CNS sanctuary site strategies. This anatomically compartmentalized approach addresses another non-hepatic TTR source outside the reach of systemic therapies.
PreclinicalProteostasis Modulation & Antibody Approaches
A 2022 Scripps Research paper describes ATF6-mediated UPR activation as a mechanism to selectively reduce secretion of destabilized TTR variants from cells via ER proteostasis factor interactions — an upstream intervention distinct from TTR binding or mRNA degradation. Separately, a 2016 Princess Margaret Cancer Centre paper describes antibody misTTR targeting residues 89–97 (a cryptic monomer-specific epitope), inhibiting fibrillogenesis at nanomolar concentrations substoichiometrically.
PreclinicalhATTR Amyloidosis: Data-Driven Pipeline Signals
Patent filing density, assignee activity, and clinical stage distribution derived from PatSnap Eureka analysis of the hATTR amyloidosis innovation landscape.
Patent Activity by Key Assignee (Distinct Records)
Alnylam dominates the dataset with 16+ distinct patent records; SOM Innovation Biotech holds 10+ records focused on CNS-penetrant COMT inhibitors.
hATTR Pipeline Stage Distribution by Modality
Two approved agents, two in Phase 3 or clinical stage, and four modalities at preclinical/early-stage — with CNS-directed approaches entirely in the latter category.
Serum TTR Reduction: Clinical Benchmarks
RNAi agents achieve the deepest hepatic TTR knockdown; tafamidis stabilizes without reducing serum TTR levels.
Key Assignee IP Filing Timeline (2011–2025)
Alnylam has filed continuously since 2016 with the most recent WO filing in 2025 expanding scope to CNS amyloidosis; ISIS/Ionis established CNS ASO IP as early as 2012.
Beyond Tafamidis: CNS-Penetrant Stabilizer Chemistry
A 2023 paper from The Scripps Research Institute demonstrates that tafamidis concentrations achieved in CSF following standard oral dosing are insufficient to stabilize TTR in the CSF compartment — the effective stabilizing concentration requiring substantially higher local drug levels than those attained with approved 20 mg or 80 mg QD doses. This pharmacological gap is the primary driver of next-generation CNS-penetrant stabilizer development.
Tolcapone's BBB permeability directly addresses this gap. A 2016 paper from Universitat Autònoma de Barcelona demonstrates tolcapone stabilizes native TTR in vivo in mice and humans and inhibits TTR cytotoxicity. Under physiological conditions, only 10–25% of plasma T4 is bound to TTR, leaving both T4-binding pockets largely unoccupied and available for pharmacological stabilizer engagement — a favorable target biology for CNS-penetrant compounds. PatSnap Analytics enables teams to map the full stabilizer IP landscape.
Iododiflunisal (IDIF), characterized in a 2019 paper from I.Q.A.C.-C.S.I.C. (Barcelona) with 131I/124I radiolabeling studies, directly interrogates brain penetration — providing mechanistic evidence for CNS-relevant stabilizer access. Benzbromarone, a repurposed uricosuric drug, was identified in a 2020 paper as a potent TTR stabilizer with IC50 and binding affinity comparable to tolcapone and tafamidis.
- Tolcapone: superior T4-pocket binding vs. tafamidis in crystal structures; BBB-permeable
- 3-O-methyltolcapone analogues (UCSF, 2023): overcome glucuronidation liability while maintaining high permeability
- Bis-furan derivatives (BSIM2, WO/EP 2016–2018): more efficient amyloid inhibition than tafamidis in vitro
- Iododiflunisal (IDIF): radiolabeled biodistribution data confirm CNS-relevant stabilizer access
- Benzbromarone: IC50 and binding affinity comparable to tolcapone and tafamidis
IP Landscape Signals & Competitive Dynamics
Key strategic implications derived from patent and literature analysis of the hATTR amyloidosis innovation dataset via PatSnap Eureka.
CNS Compartment Gap Is the Defining Unmet Need
Multiple retrieved sources converge on the fact that choroid plexus-derived TTR drives oculoleptomeningeal and CNS amyloidosis in variant carriers, and this compartment is pharmacologically inaccessible to both approved stabilizers (at current doses) and hepatically targeted RNA silencers. Developers with BBB-penetrant or intrathecal delivery platforms hold a structural competitive advantage in this segment.
Tolcapone/COMT IP Creates Dual-Patent Dependency Risk
Tolcapone/COMT inhibitor IP (SOM Innovation Biotech, Corino Therapeutics) represents a differentiated CNS-stabilizer position directly orthogonal to Alnylam's hepatic RNAi platform. The combination therapy patents covering tolcapone + RNAi could create a two-patent dependency for any CNS+systemic combination regimen — a key IP risk for competitors developing dual-compartment approaches.
Key Patent Assignees & Academic Contributors
Activity is highly concentrated among a small number of commercial assignees, with a clear demarcation between patent-heavy commercial players and publication-heavy academic groups.
| Assignee | Jurisdiction(s) | Filing Period | Focus Area | Stage |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | US, WO, EP, AU, CA, IN | 2016–2025 | TTR-inhibiting RNAi; CNS amyloidosis expansion (2025 WO) | Approved + Active |
| SOM Innovation Biotech, S.L. | US, EP, AU, SG | 2012–2023 | COMT inhibitors (tolcapone) for TTR amyloidosis; combination claims | Clinical Referenced |
| Corino Therapeutics, Inc. | US, WO, AU, CA | 2019–2021 | CSF TTR stabilization via BBB-crossing COMT inhibitors; tolcapone + RNAi combos | Clinical Stage |
| ISIS/Ionis Pharmaceuticals | HK | 2012 | Choroid plexus-directed ASO; brain-targeted TTR silencing | Inotersen Approved |
Map the complete hATTR IP landscape with PatSnap Eureka
Search 16+ Alnylam filings, SOM Innovation Biotech COMT inhibitor patents, and emerging CNS-directed approaches across all jurisdictions.
Combination Approaches & Next-Wave Pipeline Signals
Dual-compartment combination strategies, proteostasis modulation, and CNS-targeted silencing represent the field's clearest next wave of IP and pipeline activity.
Tolcapone + RNAi: Dual-Compartment Control
Corino Therapeutics holds patents (US, WO, AU, CA; 2019–2021) explicitly covering combination therapy of tolcapone with RNAi molecules for TTR amyloidosis. The biological rationale is complementary mechanism: tolcapone stabilizes residual TTR tetramers (including in the CNS compartment) while RNAi reduces hepatic TTR production, potentially achieving dual-compartment control. Signals in this dataset suggest this represents an actively prosecuted IP strategy with significant commercial implications. See how pharma teams use PatSnap for combination therapy IP mapping.
Active IP prosecution — Corino TherapeuticsCOMT Inhibitor + Multiple Agent Combinations
SOM Innovation Biotech patents (all active US, EP filings) claim tolcapone in combination with other COMT inhibitors, benzoxazole derivatives (e.g., tafamidis), iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxycycline, or epigallocatechin-3-gallate — a broad combinatorial IP landscape covering both CNS-penetrant and systemic co-treatment approaches.
10+ SOM Innovation Biotech patentsATF6 Proteostasis Modulation
A 2022 paper from The Scripps Research Institute describes ATF6-mediated unfolded protein response (UPR) activation as a mechanism to selectively reduce secretion of destabilized TTR variants from cells via endoplasmic reticulum proteostasis factor interactions, reducing the amyloidogenic precursor burden upstream of aggregation. This represents an emerging modality distinct from direct TTR binding or mRNA degradation — not yet captured in patent records within this dataset. Access PatSnap Analytics to track emerging proteostasis IP.
Preclinical — Scripps Research, 2022Brain-Penetrant & Intrathecal TTR Silencing
The ISIS/Ionis 2012 choroid plexus ASO patent, the Alnylam 2025 WO patent explicitly listing CNS amyloidosis as an indication, and the 2021 Heidelberg clinical review identifying choroid plexus and retinal TTR as unmet targets together signal that brain-penetrant or CSF-delivered TTR silencing (ASO, siRNA, or gene-editing) represents the field's clearest unmet need and a likely next wave of IP and pipeline activity. No clinical trial data for choroid plexus-directed ASOs or intrathecal siRNA delivery are present in retrieved results — this segment remains entirely preclinical. Explore the PatSnap platform for CNS drug delivery patent intelligence.
Preclinical — no clinical data identifiedhATTR Amyloidosis CNS Pipeline — Key Questions Answered
Approved liver-targeting therapies — including tafamidis and RNA-silencing agents — fail to reach TTR produced by the choroid plexus, leaving CNS and oculoleptomeningeal manifestations entirely undertreated. The choroid plexus secretes TTR into cerebrospinal fluid independently of the liver, creating a pharmacological sanctuary site inaccessible to current approved medications.
Certain TTR variants favor disease manifestations in the central nervous system or eyes, which is mostly associated with TTR production in the choroid plexus and retina. These compartments cannot be sufficiently reached by any of the approved medications. Liver transplantation, which eliminates hepatic mutant TTR production, leaves choroid plexus TTR intact, and clinical observations document continued CNS amyloid deposition and oculoleptomeningeal progression post-transplant.
A 2023 study from The Scripps Research Institute demonstrates that tafamidis concentrations achieved in CSF following standard oral dosing may be insufficient to stabilize TTR in the CSF compartment, with the effective stabilizing concentration in CSF requiring substantially higher local drug levels than those attained with approved 20 mg or 80 mg QD doses.
Tolcapone is an FDA-approved COMT inhibitor for Parkinson's disease repurposed as a potent TTR tetramer stabilizer with superior binding to the T4 pocket versus tafamidis in crystal structures. Its BBB permeability distinguishes it mechanistically from tafamidis and positions it as a direct CNS-penetrant stabilizer candidate. Corino Therapeutics holds a US patent explicitly claiming methods of stabilizing TTR tetramers in CSF via blood-brain barrier-crossing COMT inhibitors.
RNAi-mediated hepatic TTR silencing works via RNA-induced silencing complex (RISC)-mediated degradation of hepatic TTR mRNA, targeting both mutant and wild-type TTR transcripts and reducing serum TTR protein levels by more than 80–91% as documented in clinical data. The key limitation is that these agents target only the liver and cannot reach TTR produced by the choroid plexus, leaving CNS amyloidosis undertreated.
Corino Therapeutics holds patents explicitly covering combination therapy of tolcapone with RNAi molecules for TTR amyloidosis. The biological rationale is complementary mechanism: tolcapone stabilizes residual TTR tetramers (including in the CNS compartment) while RNAi reduces hepatic TTR production, potentially achieving dual-compartment control. SOM Innovation Biotech patents also claim tolcapone in combination with benzoxazole derivatives such as tafamidis, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxycycline, or epigallocatechin-3-gallate.
Still have questions? Let PatSnap Eureka search the hATTR patent and literature landscape for you.
Ask Eureka About hATTR CNS ApproachesAccelerate Your hATTR CNS Drug Discovery Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map patent landscapes, identify CNS-penetrant TTR silencing opportunities, and track next-generation pipeline activity.
References
- Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis — Labaudiniere Consulting LLC, 2016 [Paper]
- Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis — Department of Neurology, Heidelberg University Hospital, 2021 [Paper]
- Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid — Department of Chemistry, The Scripps Research Institute, 2023 [Paper]
- Stabilization of transthyretin tetramers in biological fluids — Corino Therapeutics, Inc., 2021, US [Patent]
- Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity — Universitat Autònoma de Barcelona, 2016 [Paper]
- New Therapy for Transthyretin-Associated Amyloidosis — SOM Innovation Biotech, S.L., 2020, US [Patent]
- Compositions and Methods for Treating Transthyretin (TTR) Mediated Amyloidosis — Alnylam Pharmaceuticals, Inc., 2021, US [Patent]
- Methods and compositions for treating transthyretin (TTR)-associated diseases — Alnylam Pharmaceuticals, Inc., 2025, WO [Patent]
- Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of AKCEA-TTR-LRx — National Amyloidosis Centre, UCL, 2021 [Paper]
- Treating CNS-Related Diseases Through Modulation of Thyroxine Expression — ISIS Pharmaceuticals, Inc., 2012, HK [Patent]
- Liver-directed drugs for transthyretin-mediated amyloidosis — Ionis Pharmaceuticals, 2022 [Paper]
- Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis — Alnylam Pharmaceuticals, 2016 [Paper]
- siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis — Kumamoto University, 2013, EP [Patent]
- TTR Gene — National Center for Biotechnology Information (NCBI)
- European Medicines Agency (EMA) — Approved hATTR Therapies
- The Scripps Research Institute — TTR Amyloidosis Research Program
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This page is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.